Mabe, Nathaniel W. https://orcid.org/0000-0003-2675-652X
Huang, Min
Dalton, Guillermo N.
Alexe, Gabriela https://orcid.org/0000-0002-5668-6297
Schaefer, Daniel A.
Geraghty, Anna C.
Robichaud, Amanda L.
Conway, Amy S.
Khalid, Delan
Mader, Marius M.
Belk, Julia A. https://orcid.org/0000-0003-4724-6158
Ross, Kenneth N.
Sheffer, Michal
Linde, Miles H. https://orcid.org/0000-0003-2553-2890
Ly, Nghi
Yao, Winnie
Rotiroti, Maria Caterina
Smith, Benjamin A. H. https://orcid.org/0000-0001-8802-416X
Wernig, Marius
Bertozzi, Carolyn R. https://orcid.org/0000-0003-4482-2754
Monje, Michelle https://orcid.org/0000-0002-3547-237X
Mitsiades, Constantine S.
Majeti, Ravindra https://orcid.org/0000-0002-5814-0984
Satpathy, Ansuman T. https://orcid.org/0000-0002-5167-537X
Stegmaier, Kimberly https://orcid.org/0000-0003-0218-7895
Majzner, Robbie G. https://orcid.org/0000-0001-6969-8011
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (F32 CA261035, F30 CA232541, R01-CA227942, R01-NS092597, UM1 HG012076, P01 CA217959, R35 CA210030, P01 CA217959)
Dana-Farber Cancer Institute Ungerer Fellowship award
Waxman Family Research Fund
Deutsche Forschungsgemeinschaft (DFG; MA 8492/1-1)
Philip A. Sharp Award from SU2C
Howard Hughes Medical Institute
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
Cancer Research UK
Technology Impact Award from the Cancer Research Institute, a Career Award for Medical Scientists from the Burroughs Wellcome Fund, and a Pew-Stewart Scholars Award
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS088355)
Alex's Lemonade Stand Foundation for Childhood Cancer
V foundation Taube Distinguished Scholar for Pediatric Immunotherapy at Stanford University School of Medicine
Article History
Received: 7 October 2021
Accepted: 25 May 2022
First Online: 11 July 2022
Competing interests
: K.S. consults for and has stock options in Auron Therapeutics, received grant funding from Novartis, served as an advisor for KronosBio and consulted for AstraZeneca and Bristol Meyers Squibb on topics unrelated to this manuscript. R.G.M. is a co-founder of and holds equity in Syncopation Life Sciences and Link Cell Therapies and is a consultant for Lyell Immunopharma, Innvervate Radiopharmaceuticals, NKarta, Immunai, Arovella Therapeutics, Zai lab and Aptorum Group. A.T.S. is a co-founder of Immunai and Cartography Biosciences and receives research funding from Arsenal Biosciences, Merck Research Laboratories and Allogene Therapeutics. C.R.B. is a co-founder of Redwood Biosciences (a subsidiary of Catalent), Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, Lycia Therapeutics, OliLux Biosciences, Grace Science and Virsti Therapeutics. The remaining authors declare no competing interests.